StockNews.com Begins Coverage on InspireMD (NYSE:NSPR)

Equities researchers at StockNews.com began coverage on shares of InspireMD (NYSE:NSPR) in a note issued to investors on Monday. The brokerage set a “sell” rating on the stock.

Separately, Piper Sandler restated an “overweight” rating and set a $4.50 price objective on shares of InspireMD in a research note on Tuesday, September 17th.

InspireMD Stock Performance

NYSE:NSPR opened at $2.53 on Monday. The firm has a market cap of $65.98 million, a P/E ratio of -3.37 and a beta of 0.93. InspireMD has a fifty-two week low of $1.81 and a fifty-two week high of $3.42. The firm has a 50-day simple moving average of $2.58 and a two-hundred day simple moving average of $2.60.

InspireMD (NYSE:NSPR) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.04. The business had revenue of $1.81 million during the quarter, compared to analyst estimates of $1.74 million. InspireMD had a negative net margin of 413.96% and a negative return on equity of 69.42%. During the same period last year, the business earned ($0.15) EPS. On average, equities research analysts predict that InspireMD will post -0.79 EPS for the current year.

Hedge Funds Weigh In On InspireMD

Institutional investors and hedge funds have recently modified their holdings of the company. Parkman Healthcare Partners LLC bought a new stake in InspireMD during the third quarter valued at approximately $279,000. Affiance Financial LLC bought a new stake in shares of InspireMD during the 3rd quarter valued at $492,000. Finally, Rosalind Advisors Inc. increased its stake in shares of InspireMD by 266.4% in the 2nd quarter. Rosalind Advisors Inc. now owns 2,513,641 shares of the company’s stock worth $6,272,000 after purchasing an additional 1,827,579 shares in the last quarter. 44.78% of the stock is currently owned by hedge funds and other institutional investors.

InspireMD Company Profile

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.